Trial Profile
Phase II Study of Perifosine in Patients With Refractory and Relapsed Leukemia.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Perifosine (Primary)
- Indications Acute myeloid leukaemia; Acute nonlymphocytic leukaemia; Chronic lymphocytic leukaemia; Leukaemia; Myelodysplastic syndromes; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Therapeutic Use
- Sponsors AEterna Zentaris Inc
- 16 Oct 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 08 Jun 2011 Planned end date changed from 1 Nov 2008 to 1 Dec 2011 as reported by ClinicalTrials.gov.
- 08 Jun 2011 Status changed from completed to active, no longer recruiting as reported by ClinicalTrials.gov.